Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx, Large Scale Biology

Premium

The US Patent and Trademark Office has awarded Zyomyx a patent covering a broad class of protein immobilization surfaces “having properties ideally suited for attaching proteins to biochip surfaces,” the Hayward, Calif.-based company said in a statement. The patent, US Patent 6,365,418, is entitled “Arrays of Protein-Capture Agents and Methods of Use Thereof” and is the second patent awarded to Zyomyx in the area of surface chemistry for protein biochips.

Large Scale Biology has been awarded US Patent 6,344,597 covering a new plant species used in protein production, the Vacaville, Calif.-based company said. The plant species, Nicotiana excelsiana, is used with the company’s Geneware technology for producing proteins with research and potentially therapeutic applications. “LSBC now holds a proprietary method of crossing different species of Nicotiana to produce an interspecific hybrid with increased biomass and improved utility,” LSBC said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.